Evidence map›Paper›PMID 25778445›Full record

Trial reportBritish journal of clinical pharmacology2015

Effect of nebivolol on renal nitric oxide availability and tubular function in patients with essential hypertension.

Frank H Mose, Janni M Jensen, Safa Therwani, Jesper Mortensen, Annebirthe B Hansen, Jesper N Bech, Erling B Pedersen

Open access · greenAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in British journal of clinical pharmacology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.4field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 7 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Trial
  4. Trial
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Frank H MoseUniversity Clinic in Nephrology and Hypertension, Department of Medical Research and University of Aarhus.
Janni M JensenUniversity Clinic in Nephrology and Hypertension, Department of Medical Research and University of Aarhus.
Safa TherwaniUniversity Clinic in Nephrology and Hypertension, Department of Medical Research and University of Aarhus.
Jesper MortensenDepartment of Nuclear Medicine.
Annebirthe B HansenDepartment of Clinical Biochemistry, Holstebro Hospital, Holstebro, Denmark.
Jesper N BechUniversity Clinic in Nephrology and Hypertension, Department of Medical Research and University of Aarhus.
Erling B PedersenUniversity Clinic in Nephrology and Hypertension, Department of Medical Research and University of Aarhus.
Aarhus University · DKRegional Hospital Holstebro · DK

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimsNebivolol is a selective β1 -receptor antagonist with vasodilating properties. In patients with essential hypertension, we tested the hypothesis that nebivolol increases systemic and renal nitric oxide (NO) availability using L-N(G) -monomethyl arginine (L-NMMA) as an inhibitor of NO production.

methodsIn a randomized, placebo-controlled, crossover study, patients with essential hypertension were treated with nebivolol for five days, along with a standardized diet and fluid intake. We examined the acute effects of systemic NO synthase inhibition with L-NMMA on brachial blood pressure (bBP), pulse wave velocity (PWV) and central blood pressure (cBP) estimated by applanation tonometry, glomerular filtration rate (GFR), fractional excretion of sodium (FENa ), urinary excretion of both aquaporin-2 (u-AQP2) and epithelial sodium channels (u-ENaCγ ), and plasma concentrations of nitrate/nitrite (p-NOx ) and vasoactive hormones after five days' treatment with placebo and nebivolol.

resultsNebivolol significantly reduced PWV, bBP, cBP and plasma renin, angiotensin II and aldosterone concentrations. The renal parameters, p-NOx and plasma arginine vasopressin concentration were not changed by nebivolol. There was no difference between nebivolol and placebo in the response to L-NMMA, with LMMA inducing a similar increase in PWV, bBP and cBP and a similar decrease in GFR, uAQP2 and u-ENaCγ and FENa [mean change -0.62% (95% confidence interval {CI} -0.40 to -0.84) during placebo vs. -0.57% (95% CI -0.46 to -0.68; P = 0.564) during nebivolol treatment]. Vasoactive hormones were changed to a similar extend by L-NMMA during administration of nebivolol and placebo.

conclusionsNebivolol did not change p-NOx , and inhibition of NO synthesis induced the same response in blood pressure, GFR, renal tubular function and vasoactive hormones during nebivolol and placebo. Thus, the data did not support the hypothesis that nebivolol changes vascular and renal NO availability in patients with essential hypertension.

Indexed as

Adrenergic beta-1 Receptor AntagonistsAdultAgedBlood PressureBlood Pressure Monitoring, AmbulatoryCross-Over StudiesDouble-Blind MethodFemaleGlomerular Filtration RateHumansHypertensionKidney TubulesMaleMiddle AgedNebivololNitric OxideAdrenergic beta-1 Receptor AntagonistsNebivololNitric Oxideomega-N-Methylargininearterial stiffnessblood pressureessential hypertensionfractional excretion of sodiumnebivololnitric oxide

Identifiers

PMID25778445
PMCPMC4574828
OpenAlexW1942867175

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.